These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1078 related articles for article (PubMed ID: 18993155)

  • 1. Digoxin and clinical outcomes in systolic heart failure patients on contemporary background heart failure therapy.
    Dhaliwal AS; Bredikis A; Habib G; Carabello BA; Ramasubbu K; Bozkurt B
    Am J Cardiol; 2008 Nov; 102(10):1356-60. PubMed ID: 18993155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of alpha 1-adrenergic antagonist use for benign prostatic hypertrophy on outcomes in patients with heart failure.
    Dhaliwal AS; Habib G; Deswal A; Verduzco M; Souchek J; Ramasubbu K; Aguilar D; Ma TS; Jneid HM; Bolos M; Bozkurt B
    Am J Cardiol; 2009 Jul; 104(2):270-5. PubMed ID: 19576359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence, clinical characteristics, quality of life, and prognosis of patients with congestive heart failure and isolated left ventricular diastolic dysfunction.
    Badano LP; Albanese MC; De Biaggio P; Rozbowsky P; Miani D; Fresco C; Fioretti PM
    J Am Soc Echocardiogr; 2004 Mar; 17(3):253-61. PubMed ID: 14981424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of statins, angiotensin-converting enzyme inhibitors, and beta blockers on survival in patients >or=65 years of age with heart failure and preserved left ventricular systolic function.
    Shah R; Wang Y; Foody JM
    Am J Cardiol; 2008 Jan; 101(2):217-22. PubMed ID: 18178410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of late mortality in hospitalized patients >70 years of age with systolic heart failure receiving beta blockers versus those not receiving beta blockers.
    Pascual-Figal DA; Redondo B; Caro C; Manzano S; Garrido IP; Ruipérez JA; Valdés M
    Am J Cardiol; 2008 Dec; 102(12):1711-7. PubMed ID: 19064029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure).
    van Veldhuisen DJ; Cohen-Solal A; Böhm M; Anker SD; Babalis D; Roughton M; Coats AJ; Poole-Wilson PA; Flather MD;
    J Am Coll Cardiol; 2009 Jun; 53(23):2150-8. PubMed ID: 19497441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of blood pressure and its evolving changes with the survival of patients with heart failure.
    Grigorian-Shamagian L; Gonzalez-JuAnatey JR; Vazquez R; Cinca J; Bayes-Genis A; Pascual D; Fernandez-Palomeque C; Bardaji A; Almendral J; Nieto V; Macaya C; Jimenez RP; de Luna AB;
    J Card Fail; 2008 Sep; 14(7):561-8. PubMed ID: 18722321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discharge use of angiotensin receptor blockers provides comparable effects with angiotensin-converting enzyme inhibitors on outcomes in patients hospitalized for heart failure.
    Tsuchihashi-Makaya M; Furumoto T; Kinugawa S; Hamaguchi S; Goto K; Goto D; Yamada S; Yokoshiki H; Takeshita A; Tsutsui H;
    Hypertens Res; 2010 Mar; 33(3):197-202. PubMed ID: 19960016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of beta blocker and digoxin alone and in combination for management of patients with atrial fibrillation and heart failure.
    Fauchier L; Grimard C; Pierre B; Nonin E; Gorin L; Rauzy B; Cosnay P; Babuty D; Charbonnier B
    Am J Cardiol; 2009 Jan; 103(2):248-54. PubMed ID: 19121446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Digoxin use and heart failure outcomes: results from the Valsartan Heart Failure Trial (Val-HeFT).
    Butler J; Anand IS; Kuskowski MA; Rector T; Carson P; Cohn JN;
    Congest Heart Fail; 2010; 16(5):191-5. PubMed ID: 20887614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry.
    Fonarow GC; Stough WG; Abraham WT; Albert NM; Gheorghiade M; Greenberg BH; O'Connor CM; Sun JL; Yancy CW; Young JB;
    J Am Coll Cardiol; 2007 Aug; 50(8):768-77. PubMed ID: 17707182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of all-cause mortality in chronic Chagas' heart disease in the current era of heart failure therapy.
    Theodoropoulos TA; Bestetti RB; Otaviano AP; Cordeiro JA; Rodrigues VC; Silva AC
    Int J Cardiol; 2008 Aug; 128(1):22-9. PubMed ID: 18258318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial.
    Wedel H; Demets D; Deedwania P; Fagerberg B; Goldstein S; Gottlieb S; Hjalmarson A; Kjekshus J; Waagstein F; Wikstrand J;
    Am Heart J; 2001 Sep; 142(3):502-11. PubMed ID: 11526365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug therapy of chronic heart failure in the elderly: the current state of clinical-trial evidence.
    Dulin BR; Krum H
    Curr Opin Cardiol; 2006 Jul; 21(4):393-9. PubMed ID: 16755210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical features and prognosis associated with a preserved left ventricular systolic function in a large cohort of congestive heart failure outpatients managed by cardiologists. Data from the Italian Network on Congestive Heart Failure.
    Tarantini L; Faggiano P; Senni M; Lucci D; Bertoli D; Porcu M; Opasich C; Tavazzi L; Maggioni AP
    Ital Heart J; 2002 Nov; 3(11):656-64. PubMed ID: 12506524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Failure of benefit and early hazard of bucindolol for Class IV heart failure.
    Anderson JL; Krause-Steinrauf H; Goldman S; Clemson BS; Domanski MJ; Hager WD; Murray DR; Mann DL; Massie BM; McNamara DM; Oren R; Rogers WJ;
    J Card Fail; 2003 Aug; 9(4):266-77. PubMed ID: 13680547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of digoxin among contemporary adults with incident systolic heart failure.
    Freeman JV; Yang J; Sung SH; Hlatky MA; Go AS
    Circ Cardiovasc Qual Outcomes; 2013 Sep; 6(5):525-33. PubMed ID: 24021697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atrial fibrillation and heart failure in cardiology practice: reciprocal impact and combined management from the perspective of atrial fibrillation: results of the Euro Heart Survey on atrial fibrillation.
    Nieuwlaat R; Eurlings LW; Cleland JG; Cobbe SM; Vardas PE; Capucci A; López-Sendòn JL; Meeder JG; Pinto YM; Crijns HJ
    J Am Coll Cardiol; 2009 May; 53(18):1690-8. PubMed ID: 19406345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective evaluation of beta-blocker use at the time of hospital discharge as a heart failure performance measure: results from OPTIMIZE-HF.
    Fonarow GC; Abraham WT; Albert NM; Stough WG; Gheorghiade M; Greenberg BH; O'Connor CM; Sun JL; Yancy CW; Young JB;
    J Card Fail; 2007 Nov; 13(9):722-31. PubMed ID: 17996820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.